Roche targets 2 vs GSS 12; as singular tests this chops cost to Medicare down from potentially $252 plus GP visits + additional costs from failure to diagnose lack of early treatment
Abbott 4 vs GSS 12
qiagen 1 vs GSS 12
IMHO the real value long term to governments that fund reproductive assistance is the reduction in long term fertility issues by the use of screening - as opposed to stab in the dark individual testing - the superficial symptoms go away the testing stops the condition moves to PID - and LT infertility issues
Roche targets 2 vs GSS 12; as singular tests this chops cost to...
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
71.5¢ |
Change
-0.005(0.69%) |
Mkt cap ! $163.1M | |||
| Open | High | Low | Value | Volume |
| 71.5¢ | 72.0¢ | 71.0¢ | $20.15K | 28.15K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 962 | 71.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 72.5¢ | 22427 | 5 |
View Market Depth
| Last trade - 12.54pm 10/07/2024 (20 minute delay) ? |
| GSS (ASX) Chart |